GlassScriptPhysician profile
Anthony J Cannon
NPI 1831259340
$296,445.95
in general payments reported to CMS, 2019-2025
33 companies · $39K in 2025
The $39K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $37K · 2021: $70K · 2022: $65K · 2023: $17K · 2024: $23K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Travel and Lodging: $11K · Food and Beverage: $6,726 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,510.63 |
| Travel and Lodging | $10,779.18 |
| Food and Beverage | $6,725.93 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $257,148.48 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $15,597.29 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Janssen Pharmaceuticals, INC | $6,826.40 | 2019 | |
| Abbvie INC. | $6,197.50 | 2019-2023 | Synthroid |
| Medtronic, INC. | $3,456.59 | 2021-2025 | Minimed 780g |
| Zealand Pharma US, INC. | $2,434.17 | 2020-2021 | |
| Insulet Corporation | $552.58 | 2021-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $491.36 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $354.29 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $311.33 | 2019-2024 | |
| Lilly USA, LLC | $282.44 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.73 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Dexcom, INC. | $266.79 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $257.28 | 2022-2024 | Unithroid |
| Medtronic Minimed, INC. | $246.48 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $183.35 | 2019 | |
| Amgen INC. | $182.46 | 2024 | Evenity, Tepezza |
| Ascendis Pharma Endocrinology INC | $148.38 | 2023-2025 | Yorvipath |
| Cequr Corporation | $147.31 | 2022-2024 | Cequr Simplicity |
| Becton, Dickinson and Company | $138.95 | 2019-2020 | |
| Senseonics, Incorporated | $125.00 | 2019 | |
| Corcept Therapeutics | $124.99 | 2020-2024 | Korlym |
| Mannkind Corporation | $123.13 | 2021-2024 | |
| Exelixis INC. | $118.01 | 2022 | |
| Intra-Sana Laboratories | $114.49 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Horizon Therapeutics Plc | $86.11 | 2023 | Tepezza |
| Companion Medical, INC. | $85.96 | 2020 | |
| Xeris Pharmaceuticals, INC. | $44.12 | 2023-2024 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $33.75 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $33.19 | 2024 | Isturisa, Signifor Lar |
| Radius Health, INC. | $28.75 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.09 | 2021 | |
| Beta Bionics, INC. | $11.20 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.